Antidepressant drug sales plummet as patents expire and individuals flee to safer alternatives The market for antidepressant drugs is quickly drying up as patents about long-period blockbusters like Lexapro, possessed by Forest Laboratories, and Seroquel, owned by AstraZeneca, continue steadily to expire. And because they’re unable to develop fresh multi-billion-dollar blockbuster drugs to take their locations, many drug producers are altogether ditching the antidepressant business, especially as studies continue steadily to emerge displaying that antidepressants are largely worthless and cause more damage than good. A recently available Reuters report appears to bemoan the actual fact that development of a fresh antidepressant medication ceased after it was discovered that the medication was ineffective main information .
Vidadi Yusibov, Director of the Fraunhofer USA Center for Molecular Biotechnology in Newark, Delaware. Financing for this project at the Fraunhofer USA CMB was acquired through the efforts of a congressional delegation lead by Delaware’s Senior Senator Joe Biden. Related StoriesFDA initiates NTSO actions for merchants who violated certain restrictions on sale of tobacco productsTobacco use continues to be a high threat to health insurance and economic well-being of people in ChinaBreakthrough analysis to be shown at AAO-HNSF 2015 Annual Meeting & OTO EXPOTo make the plantibodies, Baillie and his colleagues first gathered the cells that produce antibodies from individuals who was simply vaccinated against anthrax. Then genes that encode the antibody itself had been inserted into a bacterium that transfers the gene in to the plant cells.